Long-Term Outcomes of Prospective Clinical Trial HDRBrachytherapy Monotherapy in Single Day in Patients with Localized Prostate Cancer
International journal of radiation oncology, biology, physics(2023)
Abstract
With 10 years of follow-up, our prospective data are sufficiently mature to report on efficacy and toxicity outcomes, making a single implant, 2 fractions HDR-BT an attractive option for patients with localized low/intermediate-risk prostate cancer and be able to consider it a standard of care in this setting. To the best of our knowledge, this is the first report regarding single day HDR-BRT as monotherapy with a median follow-up of 10 years.
MoreTranslated text
Key words
prostate cancer,long-term,hdr-brachytherapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined